Patents Issued in May 2, 2017
  • Catalyst system for producing ketones from epoxides
    Patent number: 9637436
    Abstract: A catalyst composition is useful for producing a ketone from a compound containing at least one epoxide group, and the catalyst composition contains at least one precious metal; and at least one mixed oxide; wherein the mixed oxide contains zirconium dioxide and silicon dioxide; wherein the precious metal is supported and the support is not entirely made of the mixed oxide; and wherein a mass ratio of zirconium dioxide to silicon dioxide in the mixed oxide is 86:14 to 99.9:0.1.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: May 2, 2017
    Assignee: Evonik Degussa GmbH
    Inventors: Kévin Micoine, Ralf Meier, Jürgen Herwig, Angélique Bétard, Thomas Quandt
  • Process for the preparation of benzene derivatives from furan derivatives
    Patent number: 9637437
    Abstract: Benzene derivatives of the formula (I); wherein R1 and R2, are the same or different and independently are selected from the group consisting of hydrogen, alkyl, aralkyl, —CHO, —CH2OR3, —CH(OR4)(OR5) and —COOR6, wherein R3, R4 and R5 are the same or different and are selected from hydrogen, alkyl, aryl, alkaryl, aralkyl, alkylcarbonyl or arylcarbonyl, or wherein R4 and R5 together form an alkylene group and wherein R6 is selected from hydrogen, alkyl and aryl, are prepared in a process, which comprises: reacting a furan derivative of formula (II): wherein R1 and R2 have the meanings above, with ethylene under cycloaddition reaction conditions in the presence of an acid solvent to produce the benzene derivative, wherein the acid solvent is a carboxylic acid and is present in a weight ratio acid solvent to furan derivative from 1:1 to 250:1.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: May 2, 2017
    Assignees: FURANIX TECHNOLOGIES B.V., THE COCA-COLA COMPANY
    Inventors: Bing Wang, Gerardus Johannes Maria Gruter, Matheus Adrianus Dam, Robert Michael Kriegel
  • Preparation method of carboxylic acids or ketones using ozone, singlet state-oxygen atom or hydroxyl free radical
    Patent number: 9637438
    Abstract: A preparation method of carboxylic acids or ketones using ozone, singlet state oxygen atom O(1D) or hydroxyl free radical is provided. The method includes: filling ozone, singlet state oxygen atom O(1D) and/or hydroxyl free radical to cycloalkanes or benzenes at a pre-determined temperature and a pre-determined pressure in the presence or absence of light irradiation to produce carboxylic acids or ketones. The reaction occurs at room temperature and atmospheric pressure without producing harmful side products. The preparation method is a simple, low energy consuming, and eco-friendly method.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: May 2, 2017
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventor: Kuo-Chu Hwang
  • Derivatization of carbon
    Patent number: 9637440
    Abstract: Derivatization of an elemental carbon surface is accomplished by exposing the carbon surface to an aprotic solvent containing a hydrazone molecule of formula (I) or the corresponding salt of formula (II) wherein R1 is an organic group, and R2 is an organic group or hydrogen and decomposing the hydrazone in the presence of elemental carbon to create a carbene moiety of formula (III): which attaches to the carbon surface. The attached groups may be redox active so that the derivatized carbon may be used in an electrochemical sensor.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: May 2, 2017
    Assignee: SCHLUMBERGER TECHNOLOGY CORPORATION
    Inventors: Lynne Crawford, Nathan Lawrence, Timothy Jones
  • Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
    Patent number: 9637441
    Abstract: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid of Formula (I), and methods for making such non-natural amino acids and polypeptides.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: May 2, 2017
    Assignee: AMBRX, INC.
    Inventors: Zhenwei Miao, Junjie Liu, Thea Norman, Russell Driver
  • Photo-activated hydrogels
    Patent number: 9637442
    Abstract: Presented herein are compositions and articles including a crosslinkable polymer that produces a crosslinked polymer upon exposure to light and/or heat. In some embodiments, the compositions are used to fill fine lines and wrinkles to provide a cosmetic benefit. In other embodiments, the compositions and articles have desirable release properties for embedded materials.
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: May 2, 2017
    Assignee: L'Oreal
    Inventors: Vincenzo Casasanta, III, William Brenden Carlson, Gregory David Phelan
  • Graphene quantum dots and method of making
    Patent number: 9637443
    Abstract: A method for forming a graphene quantum dot product includes adding an organic starting material to a vessel and heating the organic starting material to a temperature within 20° C. of the organic starting material's boiling temperature for a time no longer than ten minutes to form graphene quantum dots. A method for sensing a graphene quantum dot includes forming a graphene quantum dot, exciting the graphene quantum dot with light having a first wavelength, measuring light emitted by the excited graphene quantum dot at a second wavelength different from the first wavelength. A graphene quantum dot includes carbon atoms and nitrogen atoms where the nitrogen atoms are present within the graphene quantum dot at a level between 6.0% and 11.0% of a level of carbon atoms present in the graphene quantum dot.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: May 2, 2017
    Assignee: University of North Dakota
    Inventors: Julia Xiaojun Zhao, Xu Wu
  • Bisoxime ester photoinitiator and preparation method and use thereof
    Patent number: 9637444
    Abstract: A bisoxime ester photoinitiator as represented by general formula (I). By introducing a bisoxime ester group and a cycloalkylalkyl group into the chemical structure, this photoinitiator not only has excellent performance in aspects of storage stability, photosensitivity, developability, pattern integrity, and the like, but also exhibits obviously improved photosensitivity and thermal stability compared to similar photoinitiators.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: May 2, 2017
    Assignees: Changzhou Tronly Advanced Electronic Materials Co., Ltd., Changzhou Tronly New Electronic Materials Co., Ltd.
    Inventor: Xiaochun Qian
  • Isocyanate production process using composition containing carbamic acid ester and aromatic hydroxy compound, and composition for transfer and storage of carbamic acid ester
    Patent number: 9637445
    Abstract: An object of the present invention is to provide an isocyanate production process, which is free of the various problems found in the prior art, and which uses a composition containing a carbamic acid ester and an aromatic hydroxy compound when producing isocyanate without using phosgene, as well as a carbamic acid ester composition for transferring or storing carbamic acid ester. The present invention discloses an isocyanate production process including specific steps and using a composition containing a carbamic acid ester and an aromatic hydroxy compound, as well as a composition for transfer or storage of carbamic acid ester comprising the carbamic acid ester and the specific aromatic hydroxy compound.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: May 2, 2017
    Assignee: Asahi Kasei Chemicals Corporation
    Inventors: Masaaki Shinohata, Nobuhisa Miyake
  • Fluorine-containing nitrile-oxide compound
    Patent number: 9637446
    Abstract: A stable and easily producible compound of the formula (I): wherein R1 represents a hydrocarbon group; and R2 and R3 represent each independently a hydrogen atom or a hydrocarbon group: provided that in at least one of R1, R2 and R3, at least one hydrogen atoms are substituted by a fluorine atom, and each of R1, R2 and R3 is attached via its carbon atom to a carbon atom to which a nitrileoxide group is attached.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: May 2, 2017
    Assignees: DAIKIN INDUSTRIES, LTD., TOKYO INSTITUTE OF TECHNOLOGY
    Inventors: Tadashi Kanbara, Tsuyoshi Noguchi, Haruhiko Mouri, Toshikazu Takata, Yasuhito Koyama, Satoshi Uchida, ChenGang Wang, Cheawchan Sumitra
  • Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof
    Patent number: 9637447
    Abstract: The invention relates to the molecule having formula (I), as well as the enantiomers thereof, and to the use of same in the treatment of ADHD, narcolepsy or idiopathic hypersomnia.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: May 2, 2017
    Assignee: NLS Pharma AG
    Inventor: Eric Konofal
  • Resveratrol selenide preparation for treating cancer
    Patent number: 9637448
    Abstract: A trans-resveratrol selenide for treating cancer has such a structure as: wherein hydroxyls at position 3, 4 and 5 are replaceable, at least one hydroxyl at position 3, 4, 5 is replaced with R, R is alkali metal ion and selenium coordination complex, and The trans-resveratrol selenide preparation is able to treat various cancers, such as lung cancer, lymphoma, stomach cancer, liver cancer, small intestine cancer, colorectal cancer and gynecologic cancer, and has a good curative effect.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: May 2, 2017
    Assignee: Shanghai Ai Qi Ecological Technology Co., Ltd.
    Inventors: Gong Chen, Kunyuan Song
  • Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-?, ?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic-acid
    Patent number: 9637449
    Abstract: Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: May 2, 2017
    Assignee: Pfizer Inc.
    Inventors: Joseph Francis Krzyzaniak, Jason Albert Leonard
  • Octahydrocyclopentapyrroles, their preparation and use
    Patent number: 9637450
    Abstract: The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatment of diseases characterized by excessive lipofuscin accumulation in the retina.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 2, 2017
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Konstantin Petrukhin, Christopher Cioffi, Graham Johnson, Nicoleta Dobri, Emily Freeman, Ping Chen, Michael Conlon, Lei Zhu
  • Indole compound
    Patent number: 9637451
    Abstract: [Problem] To provide a compound useful as a MT1 and/or MT2 receptor agonist. [Solution] The present inventors have studied on MT1 and/or MT2 receptor agonists, and have confirmed that indole compounds have the activity. As a result, the present invention is accomplished. That is, a compound represented by formula (I) or a salt thereof according to the present invention has a MT1 and/or MT2 receptor agonistic activity and has a low ability of migrating into central nervous system. Therefore, the compound or a salt thereof can be used as a peripheral MT1 and/or MT2 receptor agonist, and therefore can be used as a therapeutic and/or prophylactic agent for urinary incontinence, particularly stress urinary incontinence and mixed urinary incontinence.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: May 2, 2017
    Inventors: Shunichiro Matsumoto, Takafumi Shimizu, Tomoyuki Saito, Takatoshi Kanayama, Hiroaki Tanaka, Chiharu Mori, Kazuhiro Yokoyama, Shigeo Matsui
  • 3-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitors
    Patent number: 9637453
    Abstract: The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6 and HDAC11, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: May 2, 2017
    Assignee: Forma Therapeutics, Inc.
    Inventors: Pui Yee Ng, Heather Davis, Kenneth W. Bair, Aleksandra Rudnitskaya, Xiaozhang Zheng, Bingsong Han, Nicholas Barczak, David R. Lancia, Jr.
  • Fluorine substituted cyclic amine compounds and preparation methods, pharmaceutical compositions, and uses thereof
    Patent number: 9637454
    Abstract: The present invention relates to the field of pharmaceutical chemistry and pharmacotherapeutics, and in particular to compounds of general formula I, racemates, R-isomers, S-isomers, and pharmaceutically acceptable salts thereof and their mixtures, and the preparation methods thereof and a pharmaceutical composition containing the compounds and uses thereof as an acetylcholine esterase inhibitor.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: May 2, 2017
    Assignee: SHANGHAI INSTITUTE OF MATERIA MADICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Hong Liu, Haiyan Zhang, Yu Zhou, Yan Fu, Hualiang Jiang, Xican Tang, Kaixian Chen
  • Heterocyclic sulfone ROR? modulators
    Patent number: 9637455
    Abstract: Described are ROR? modulators of the formula (I), [INSERT CHEMICAL STRUCTURE HERE] or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: May 2, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jingwu Duan, T. G. Murali Dhar, Bin Jiang, Ananta Karmakar, Arun Kumar Gupta, Zhonghui Lu
  • 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
    Patent number: 9637456
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: May 2, 2017
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • Process for the stereoselective preparation of a pyrazole-carboxamide
    Patent number: 9637457
    Abstract: The present invention relates to a process for the enantioselective preparation of the compound of formula (Ib), which process comprises a) reducing the (E)- or (Z)-form of a compound of formula (II), with an enantioselective reagent to a compound of formula (IIIa), and b) acylating the compound of formula (IIIa) with the compound of formula (IV), or c) coupling the compound of formula (IV) with the compound of formula (II), to give a compound of formula (V) and d) reducing compound of formula (V) in the presence of hydrogen, a catalyst and a chiral ligand, to the compound of formula (Ib).
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: May 2, 2017
    Assignee: Syngenta Participations AG
    Inventors: Raphael Dumeunier, Jilali Kessabi, Sebastian Volker Wendeborn, Hannes Nussbaumer
  • Pyrimidine carboxamides as sodium channel blockers
    Patent number: 9637458
    Abstract: The present disclosure provides substituted pyrimidine carboxamides of Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein A1, X, A2, W1, W2, W3, E, Z, and R4 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: May 2, 2017
    Inventors: Jeffrey Lockman, Chiyou Ni, Jae Hyun Park, Minnie Park, Bin Shao, Laykea Tafesse, Jiangchao Yao, Mark A. Youngman
  • Sodium and calcium salts of dihydroquinazoline derivative and use thereof as antiviral agents
    Patent number: 9637459
    Abstract: The invention relates to sodium and calcium salts of {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid and solvates thereof, to the use thereof in a method of treatment and/or prophylaxis of virus infections and to the use thereof for producing drugs for use in methods of treatment and/or prophylaxis of diseases, more particularly the use thereof as antiviral agents, more particularly against cytomegaloviruses.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: May 2, 2017
    Assignee: AICURIS GMBH & CO KG.
    Inventors: Alfons Grunenberg, Mathias Berwe, Birgit Keil, Edwin Aret, Kerstin Paulus, Wilfried Schwab
  • Isotopically enriched arylsulfonamide CCR3 antagonists
    Patent number: 9637460
    Abstract: Provided herein are isotopically enriched arylsulfonamides, for example, of Formula I, that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disease, disorder, or condition.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: May 2, 2017
    Assignee: Axikin Pharmaceuticals, Inc.
    Inventors: Tai Wei Ly, Garrett Thomas Potter
  • Electrical connection structure
    Patent number: 9637461
    Abstract: An electrical connection structure includes: a first metal member including copper or a copper alloy, a plated tin layer being formed on at least a portion of the first metal member; a second metal member that is electrically connected or connectable to the first metal member; and a surface treating layer formed on the surface of the first metal member. The surface treating layer is formed by applying a surface treating agent containing base oil and a metal affinity compound having a lipophilic group and an affinity group that has an affinity for metal. The metal affinity compound contains an adduct between an acidic alkyl phosphate ester and an azole compound and an adduct between an acidic alkyl phosphate ester and a metal and/or an organic amine compound.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: May 2, 2017
    Assignees: AUTONETWORKS TECHNOLOGIES, LTD., SUMITOMO WIRING SYSTEMS, LTD., SUMITOMO ELECTRIC INDUSTRIES, LTD., KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
    Inventors: Hideki Nomura, Hiroki Hirai, Junichi Ono, Takuji Ootsuka, Takehiro Hosokawa, Tatsuya Hase, Kazuo Nakashima, Kazuhiro Goto, Makoto Mizoguchi
  • Process for the preparation of -iodoamides
    Patent number: 9637462
    Abstract: The present invention provides new stable crystalline N-iodoamides-1-iodo-3,5,5-trimethylhydantoin (1-ITMH) and 3-iodo-4,4-dimethyl-2-oxazolidinone (IDMO). The present invention further provides a process for the preparation of organic iodides using N-iodoamides of this invention and recovery of the amide co-products from waste water.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: May 2, 2017
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Gennady Nisnevich, Kseniya Kulbitski, Mark Gandelman, Alexander Artaryan
  • Utilizing a multiphase reactor for the conversion of biomass to produce substituted furans
    Patent number: 9637463
    Abstract: The present disclosure provides methods to produce substituted furans (e.g., halomethylfurfural, hydroxymethylfurfural, and furfural), by acid-catalyzed conversion of biomass using a gaseous acid in a multiphase reactor, such as a fluidized bed reactor.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: May 2, 2017
    Assignee: MICROMIDAS, INC.
    Inventors: Makoto Nathanael Masuno, John Bissell, II, Ryan L. Smith, Brian Higgins, Alex B. Wood
  • Nonionic surfactant and method for producing nonionic surfactant
    Patent number: 9637464
    Abstract: The nonionic surfactant of the present invention has a structure represented by formula (1): wherein each of R1 and R4 is a hydrogen atom or an alkyl group; each of R2, R3, R5, and R6 is a hydrocarbon group that may contain an ether bond; R2 and R3 may be bonded together to form a cyclic structure, and R5 and R6 may be bonded together to form a cyclic structure; AO represents an oxyalkylene group or oxyalkylene groups that may be the same or different; and n is a number of 1 to 1000 and represents an average addition molar number of the oxyalkylene group or oxyalkylene groups.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: May 2, 2017
    Assignee: Niitaka Co., Ltd.
    Inventors: Masaki Morita, Sana Ito
  • 3? Equatorial-fluorine-substituted neuraminidase inhibitor compounds, compositions and methods for the use thereof as anti-virals
    Patent number: 9637465
    Abstract: Equatorial 2,3-fluorinated glycosides compounds of formula (I) useful for the treatment or prophylaxis of viral infection, particularly viral influenza, the methods for their preparation, and their pharmaceutical compositions. The therapeutic effect is achieved via inhibition of viral neuraminidases.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: May 2, 2017
    Assignee: The University of British Columbia
    Inventors: Stephen Withers, Hongming Chen, Ricardo Resende, Jennifer Lois Breschkin
  • Liquid crystal compound having 2, 6-difluorophenyl ether structure and liquid crystal composition thereof
    Patent number: 9637466
    Abstract: The present invention relates to a compound having 2,6-difluorophenyl ether structure and useful as an organic electronic material and a medicine/agrochemical, particularly a material for liquid crystal display devices, and also relates to an effective method for producing the same. The present invention provides a compound represented by general formula (1) and also provides a liquid crystal composition containing the compound and a liquid crystal display device using the liquid crystal composition. A liquid crystal composition exhibiting low viscosity and a liquid crystal phase within a wide temperature range can be produced by using the compound represented by the general formula (1) as a component of the liquid crystal composition. Thus, the compound is very useful as a constituent component of a liquid crystal composition for a liquid crystal display device required to have, fast response.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: May 2, 2017
    Assignee: DIC CORPORATION
    Inventors: Kenta Tojo, Tetsuo Kusumoto
  • Treatment of inflammatory bowel disease
    Patent number: 9637467
    Abstract: Disclosed herein is a method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound having a structure according to Formula I wherein X, Y, B, R2, R3, R4, R5, R6 and n have the meanings found herein.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: May 2, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Yariv Donde, Jeremiah H. Nguyen, Karen M. Kedzie, Daniel W. Gil, John E. Donello, Wha-Bin Im
  • Process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine
    Patent number: 9637468
    Abstract: The invention discloses improved processes for manufacturing a compound, 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine, its monohydrochloride salt and intermediates thereof.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: May 2, 2017
    Assignee: Novartis AG
    Inventors: Dietmar Flubacher, Nicole Bieri, Murat Acemoglu, Pascal Michel, Rasmus Mose, Hans Stettler, Maria Caterina Testa, Joerg Brozio, Frank Schaefer
  • Pyridine derivative
    Patent number: 9637469
    Abstract: Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with URAT1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and Lesch-Nyhan syndrome.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: May 2, 2017
    Assignee: Teijin Pharma Limited
    Inventors: Akinobu Maruyama, Hirofumi Kamada, Mika Fujinuma, Susumu Takeuchi, Hiroshi Saitoh, Yoshimasa Takahashi
  • Treatment for substance use disorders and stress disorders
    Patent number: 9637470
    Abstract: Treatments are described for stress disorders and substance use disorders, for example, substance use disorders associated with use of alcohol, cocaine, amphetamines, and the like.
    Type: Grant
    Filed: February 22, 2014
    Date of Patent: May 2, 2017
    Inventors: Thomas F. Newton, Colin N. Haile
  • Hydroxyindalpine derivatives and their medical use
    Patent number: 9637471
    Abstract: The present invention relates to hydroxyindalpine derivatives of formula (I) as defined herein and pharmaceutical compositions comprising these compounds, as well as their medical use, particularly in the treatment or prevention of gastrointestinal diseases/disorders, such as constipation and functional dyspepsia.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: May 2, 2017
    Assignee: Technische Universitat Munchen
    Inventors: Arne Skerra, Michael Muller, Michael Schemann, Thomas Berger
  • Substituted 6,5-fused bicyclic heteroaryl compounds
    Patent number: 9637472
    Abstract: The present invention relates to substituted 6,5-fused bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: May 2, 2017
    Assignee: Epizyme, Inc.
    Inventors: Kevin Wayne Kuntz, Edward James Olhava, Richard Chesworth, Kenneth William Duncan
  • Acrylamide derivatives as antimalarial agents
    Patent number: 9637473
    Abstract: The invention relates to novel acrylamide derivatives of the formula I wherein R1, R2, R3, X, and ring A are as defined in the description, and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing those compounds and their use as medicaments for the treatment or prevention of protozoal infections, such as especially malaria.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 2, 2017
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Hamed Aissaoui, Christoph Boss, Claire-Lise Ciana, Thierry Kimmerlin, Romain Siegrist
  • Aurora A kinase inhibitor
    Patent number: 9637474
    Abstract: The present invention provides an aminopyridine compound, or a pharmaceutically acceptable salt thereof, that inhibits Aurora A and, therefore may be useful in treating cancer.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: May 2, 2017
    Assignee: Eli Lilly and Company
    Inventor: James Robert Henry
  • Compounds for treating cancer
    Patent number: 9637475
    Abstract: A method of preventing, inhibiting, or treating cancer that includes contacting a cell with at least one compound of formula (Ia) or a pharmaceutically acceptable salt thereof: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R? is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3)alkyl group.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: May 2, 2017
    Assignees: ABIVAX, CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Pierre Roux, Florence Mahuteau, Romain Najman, Jamal Tazi, Gilles Gadea, Didier Scherrer, Carsten Brock, Nathalie Cahuzac
  • Atrasentan mandelate salts
    Patent number: 9637476
    Abstract: The present disclosure relates to: (a) mandelate salts of atrasentan, (b) pharmaceutical compositions comprising an atrasentan mandelate salt, and, optionally, one or more additional therapeutic agents; (b) methods of using an atrasentan mandelate salt to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising a first pharmaceutical composition comprising an atrasentan mandelate salt, and, optionally, a second pharmaceutical composition comprising one or more additional therapeutic agents; (d) methods for the preparation of an atrasentan mandelate salt; and (e) atrasentan mandelate salts prepared by such method.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: May 2, 2017
    Assignee: AbbVie Inc.
    Inventors: Yuchuan Gong, Geoff G. Zhang
  • Therapeutic substituted pyrroles
    Patent number: 9637477
    Abstract: Disclosed herein are compounds of the formula: compositions thereof, and methods for the treatment of glaucoma, reducing intraocular pressure, and other prostaglandin EP2 mediated disease and disorders.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: May 2, 2017
    Assignee: ALLERGAN, INC.
    Inventor: David W. Old
  • Antiviral compounds and uses thereof
    Patent number: 9637478
    Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: May 2, 2017
    Assignee: AbbVie Inc.
    Inventors: David A. Betebenner, John K. Pratt, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Douglas K. Hutchinson, Warren M. Kati, Allan C. Krueger, Kenton L. Longenecker, Clarence J. Maring, John T. Randolph, Todd W. Rockway, Michael D. Tufano, Rolf Wagner, Dachun Liu
  • Tartrate salt of 5-chloro-thiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxo-pyrrolidin-1-yl)-benzenesulfonylamino]-3-(4-methyl-piperazin-1-yl)-3-oxo-propyl]amide
    Patent number: 9637479
    Abstract: The invention relates to the tartrate salt of 5-chloro-thiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxo-pyrrolidin-1-yl)-benzenesulfonylamino]-3-(4-methyl-piperazin-1-yl)-3-oxo-propyl]amide, to its crystalline form, to its preparation and to its therapeutic use.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: May 2, 2017
    Assignee: Sanofi
    Inventors: Laurent Lafferrere, Sébastien Villion, Sandrine Gauthier, André Bourbon
  • Parasite- and hygienic pest-controlling agent
    Patent number: 9637480
    Abstract: There is provided a novel agent for controlling harmful arthropods or nematodes that are parasites and hygienic pests for animals. An ecto- or endo-parasiticide for mammals or the like comprising as active ingredient, one or more selected from substituted benzamide compounds of formula (1) or salts thereof: wherein A1 is C—X3 or nitrogen atom, etc., A2 and A3 are C—H, etc., A4 is C—H or nitrogen atom, etc., G is G-2a, etc., W is oxygen atom or sulfur atom, X1 is halogen atom, trifluoromethyl, etc., X2 is hydrogen atom, halogen atom, trifluoromethyl, etc., X3 is hydrogen atom, halogen atom, etc., Y1 is hydrogen atom, halogen atom, methyl, etc., R1 is trifluoromethyl, etc., R2 is E-3a, etc., R3 is hydrogen atom, etc., p is an integer of 0 to 2.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: May 2, 2017
    Assignee: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Takeshi Mita, Yukihiro Maizuru, Ken-ichi Toyama, Motoyoshi Iwasa, Hotaka Imanaka, Hiroto Matsui
  • Liver X receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions
    Patent number: 9637481
    Abstract: Described herein are liver X receptor (LXR) modulators and methods of utilizing LXR modulators in the treatment of dermal diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: May 2, 2017
    Assignee: Ralexar Therapeutics, Inc.
    Inventor: Raju Mohan
  • Isoxazoline hydroxamic acid derivatives as LpxC inhibitors
    Patent number: 9637482
    Abstract: This invention pertains generally to compounds of Formula I and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention pertains to methods and compositions for treating infections caused by Gram-negative bacteria.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: May 2, 2017
    Assignee: Novartis AG
    Inventors: Jiping Fu, Xianming Jin, Subramanian Karur, Guillaume Lapointe, Patrick Lee, Zachary Kevin Sweeney
  • Heterocyclic compound
    Patent number: 9637483
    Abstract: Provided is a compound or a salt thereof, which has an excellent JAK inhibitory action, and is useful as a prophylactic or therapeutic agent for autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's syndrome, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: May 2, 2017
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Masato Yoshida, Hiroyuki Nagamiya, Yusuke Ohba, Masaki Seto, Takatoshi Yogo, Satoshi Sasaki, Norihito Tokunaga, Kazuyoshi Aso
  • Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof
    Patent number: 9637484
    Abstract: Cycloalkyl acid derivatives, a preparation method thereof, and a pharmaceutical application thereof are described. In particular, a cycloalkyl acid derivative represented by general formula (I) and a medical salt thereof, a preparation method thereof, and an application of the cycloalkyl acid derivative and the medical salt thereof as URAT1 inhibitors, and particularly as therapeutic agents for diseases related to an abnormal uric acid level are described, wherein definitions of substituent groups in general formula (I) are the same as the definitions in the specification.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: May 2, 2017
    Assignees: SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD., JIANGSU HENGRUI MEDICINE CO., LTD.
    Inventors: Jianbiao Peng, Piaoyang Sun, Jiong Lan, Chunyan Gu, Xiaotao Li, Bonian Liu, Chunzhou Han, Qiyue Hu, Fangfang Jin, Qing Dong, Guoqing Cao
  • 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
    Patent number: 9637485
    Abstract: The invention provides novel compounds having the general formula: wherein R1 to R6, W and X are as described herein and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: May 2, 2017
    Assignee: Hoffmann-LA Roche Inc.
    Inventors: Xingchun Han, Min Jiang, Jianhua Wang, Chengang Zhou, Yongguang Wang, Song Yang
  • Btk inhibitors
    Patent number: 9637486
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof. Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: May 2, 2017
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Jian Liu, Ronald M. Kim, Joseph Kozlowski, Arto D. Krikorian, Rajan Anand
  • Purinone compounds as kinase inhibitors
    Patent number: 9637487
    Abstract: Disclosed herein are compounds of Formula (I) that are useful as inhibitors of Bruton's tyrosine kinase: where R6-R10 are as defined herein. Also disclosed are pharmaceutical compositions that include the compounds. The compounds may be used, for example, to treat autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: May 2, 2017
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, Zhaozhong J. Jia, David J. Loury